Sorrento Therapeutics Inc

NASDAQ:SRNE   3:59:58 PM EDT
7.02
-0.30 (-4.10%)
Products, Regulatory, Other Pre-Announcement

Sorrento Therapeutics Says China's National Medical Products Administration Clears Lee's Pharmaceutical To Conduct Phase III Trial Of Socazolimab

Published: 03/08/2021 03:45 GMT
Sorrento Therapeutics Inc (SRNE) - Lee’s Pharmaceutical Announces Its Anti-pd-l1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial As a First-line Treatment of Extensive-stage Small-cell Lung Cancer.
China's National Medical Products Administration Clears Lee's Pharm to Conduct a Phase Iii Trial of Socazolimab.
Shanghai Chest Hospital is Expected to Initiate Patient Recruitment in Q2.
Lee's Pharm Expects to File New Drug Application for Socazolimab in Recurrent Or Metastatic Cervical Cancer in Q2.